Targeting EGFR in glioblastoma: lessons from a disappointing journey. A systematic review

View at publisher Summarise with VIRAT
Authors: Ali Berro, Ahmad Assi, Sarah Samhat, Grace SABRA, Rita HADDAD, Yara Gebran, Ronald F. Moussa
Cited by: 0
References: 63

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: This review aims to review the efficacy and toxicity of anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in the management of glioblastoma. METHODS: A systematic review was completed utilizing PubMed, Cochrane, and Embase databases up to February 2025. Boolean operators and the MeSH term "glioma" were used, along with relevant keywords related to EGFR. RESULTS: First- and second-generation EGFR-focused TKIs performed poorly in patients with GBM. The use of erlotinib in combination with radiotherapy, alkylating agents, and anti-angiogenic agents yielded the best outcomes in patients with newly diagnosed GBM. CONCLUSIONS: EGFR-focused TKIs were largely disappointing as a treatment for GBM. Longstanding issues, including treatment resistance, tumor heterogeneity, and blood-brain barrier penetration persist. Future efforts must focus on tackling these issues, and prioritizing patient selection via biomarkers.

Fields of Study & Subjects

Glioma Diagnosis and Treatment HER2/EGFR in Cancer Research Lung Cancer Treatments and Mutations

Publication details

Journal / source
Journal of Neurosurgical Sciences
Volume
70
Issue
3
Pages
233–241
Publication date
26 March 2026
Language
EN